BICYCLE THERAPEUTICS PLC
BCYCDrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
BT8009
Urinary Bladder Neoplasm
Gemcitabine + cisplatin Or carboplatin
Metastatic Urothelial Cancer
Zelenectide pevedotin (BT8009)
Non-Small Cell Lung Cancer
BT5528
Advanced Solid Tumor Historically Known for High EphA2 Expression
BT7480
Advanced Solid Tumor
nuzefatide pevedotin (BT5528)
Pancreatic Ductal Adenocarcinoma (PDAC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BT8009 | Phase 3 | Urinary Bladder Neoplasm | - | - |
Gemcitabine + cisplatin Or carboplatin | Phase 3 | Metastatic Urothelial Cancer | - | - |
Zelenectide pevedotin (BT8009) | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BT5528 | Phase 2 | Advanced Solid Tumor Historically Known for High EphA2 Expression | - | - |
BT7480 | Phase 2 | Advanced Solid Tumor | - | - |
nuzefatide pevedotin (BT5528) | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | - | - |